Literature DB >> 31694954

Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Lisa J Henderson1, Lauren B Reoma1, Joseph A Kovacs2, Avindra Nath3.   

Abstract

A disease of more than 39.6 million people worldwide, HIV-1 infection has no curative therapy. To date, one man has achieved a sterile cure, with millions more hoping to avoid the potential pitfalls of lifelong antiretroviral therapy and other HIV-related disorders, including neurocognitive decline. Recent developments in immunotherapies and gene therapies provide renewed hope in advancing efforts toward a sterilizing or functional cure. On the horizon is research concentrated in multiple separate but potentially complementary domains: vaccine research, viral transcript editing, T-cell effector response targeting including checkpoint inhibitors, and gene editing. Here, we review the concept of targeting the HIV-1 tissue reservoirs, with an emphasis on the central nervous system, and describe relevant new work in functional cure research and strategies for HIV-1 eradication. This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

Entities:  

Keywords:  CRISPR/Cas9; HIV-1; brain; checkpoint inhibitors; functional cure; latency; reservoir

Year:  2020        PMID: 31694954      PMCID: PMC7000960          DOI: 10.1128/JVI.00375-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  186 in total

1.  Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.

Authors:  Xiaobin Lu; Laurent Humeau; Vladimir Slepushkin; Gwendolyn Binder; Qiao Yu; Tatiana Slepushkina; Ziping Chen; Randall Merling; Brian Davis; Yung-Nien Chang; Boro Dropulic
Journal:  J Gene Med       Date:  2004-09       Impact factor: 4.565

2.  Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative.

Authors:  Sara Richter; Cristina Parolin; Barbara Gatto; Claudia Del Vecchio; Egidio Brocca-Cofano; Arnaldo Fravolini; Giorgio Palù; Manlio Palumbo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.

Authors:  Matthew M Burke; Harriet M Kluger; Marjorie Golden; Kevin N Heller; Axel Hoos; Mario Sznol
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

Review 4.  HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review.

Authors:  Joanna Smoleń-Dzirba; Magdalena Rosińska; Janusz Janiec; Marek Beniowski; Mariusz Cycoń; Jolanta Bratosiewicz-Wąsik; Tomasz J Wąsik
Journal:  AIDS Rev       Date:  2017-12       Impact factor: 2.500

5.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Authors:  Cynthia L Gay; Ronald J Bosch; Justin Ritz; Jason M Hataye; Evgenia Aga; Randall L Tressler; Stephen W Mason; Carey K Hwang; Dennis M Grasela; Neelanjana Ray; Josh C Cyktor; John M Coffin; Edward P Acosta; Richard A Koup; John W Mellors; Joseph J Eron
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

6.  Breaking the code of DNA binding specificity of TAL-type III effectors.

Authors:  Jens Boch; Heidi Scholze; Sebastian Schornack; Angelika Landgraf; Simone Hahn; Sabine Kay; Thomas Lahaye; Anja Nickstadt; Ulla Bonas
Journal:  Science       Date:  2009-12-11       Impact factor: 47.728

7.  Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance.

Authors:  Xiaobin Lu; Qiao Yu; Gwendolyn K Binder; Ziping Chen; Tatiana Slepushkina; John Rossi; Boro Dropulic
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

9.  Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.

Authors:  Richard Brad Jones; Rachel O'Connor; Stefanie Mueller; Maria Foley; Gregory L Szeto; Dan Karel; Mathias Lichterfeld; Colin Kovacs; Mario A Ostrowski; Alicja Trocha; Darrell J Irvine; Bruce D Walker
Journal:  PLoS Pathog       Date:  2014-08-14       Impact factor: 6.823

10.  Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection.

Authors:  Meghan Rothenberger; John E Wagner; Ashley Haase; Douglas Richman; Bartosz Grzywacz; Matthew Strain; Steven Lada; Jacob Estes; Courtney V Fletcher; Anthony T Podany; Jodi Anderson; Thomas Schmidt; Steve Wietgrefe; Timothy Schacker; Michael R Verneris
Journal:  Open Forum Infect Dis       Date:  2018-05-22       Impact factor: 3.835

View more
  19 in total

1.  Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.

Authors:  Thanigaimalai Pillaiyar; Philipp Flury; Nadine Krüger; Haixia Su; Laura Schäkel; Elany Barbosa Da Silva; Olga Eppler; Thales Kronenberger; Tianqing Nie; Stephanie Luedtke; Cheila Rocha; Katharina Sylvester; Marvin R I Petry; James H McKerrow; Antti Poso; Stefan Pöhlmann; Michael Gütschow; Anthony J O'Donoghue; Yechun Xu; Christa E Müller; Stefan A Laufer
Journal:  J Med Chem       Date:  2022-06-16       Impact factor: 8.039

Review 2.  Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program.

Authors:  Patricia K Riggs; Antoine Chaillon; Guochun Jiang; Scott L Letendre; Yuyang Tang; Jeff Taylor; Andrew Kaytes; Davey M Smith; Karine Dubé; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2022-10-19       Impact factor: 5.495

3.  Oregano Oil and Its Principal Component, Carvacrol, Inhibit HIV-1 Fusion into Target Cells.

Authors:  S Mediouni; J A Jablonski; S Tsuda; A Barsamian; C Kessing; A Richard; A Biswas; F Toledo; V M Andrade; Y Even; M Stevenson; T Tellinghuisen; H Choe; M Cameron; T D Bannister; S T Valente
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

4.  Genetically edited CD34+ cells derived from human iPS cells in vivo but not in vitro engraft and differentiate into HIV-resistant cells.

Authors:  Maelig G Morvan; Fernando Teque; Lin Ye; Mary E Moreno; Jiaming Wang; Scott VandenBerg; Cheryl A Stoddart; Yuet Wai Kan; Jay A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-18       Impact factor: 11.205

5.  Programmed death ligand-1 induction restrains the cytotoxic T lymphocyte response against microglia.

Authors:  Priyanka Chauhan; Shuxian Hu; Sujata Prasad; Wen S Sheng; James R Lokensgard
Journal:  Glia       Date:  2020-10-31       Impact factor: 7.452

6.  Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice.

Authors:  Hang Su; Sruthi Sravanam; Brady Sillman; Emiko Waight; Edward Makarov; Saumi Mathews; Larisa Y Poluektova; Santhi Gorantla; Howard E Gendelman; Prasanta K Dash
Journal:  J Neuroimmune Pharmacol       Date:  2021-09-15       Impact factor: 4.147

Review 7.  Effect of Opioid Use on Immune Activation and HIV Persistence on ART.

Authors:  Livio Azzoni; David Metzger; Luis J Montaner
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-25       Impact factor: 7.285

8.  Targeting HIV-1 RNase H: N'-(2-Hydroxy-benzylidene)-3,4,5-Trihydroxybenzoylhydrazone as Selective Inhibitor Active against NNRTIs-Resistant Variants.

Authors:  Angela Corona; Ester Ballana; Simona Distinto; Dominga Rogolino; Claudia Del Vecchio; Mauro Carcelli; Roger Badia; Eva Riveira-Muñoz; Francesca Esposito; Cristina Parolin; José A Esté; Nicole Grandi; Enzo Tramontano
Journal:  Viruses       Date:  2020-07-06       Impact factor: 5.048

9.  Development and optimization of a simian immunodeficiency virus (SIV) droplet digital PCR (ddPCR) assay.

Authors:  Samuel Long; Brian Berkemeier
Journal:  PLoS One       Date:  2020-10-09       Impact factor: 3.240

10.  Synergistic Chromatin-Modifying Treatments Reactivate Latent HIV and Decrease Migration of Multiple Host-Cell Types.

Authors:  Alexandra Blanco; Tarun Mahajan; Robert A Coronado; Kelly Ma; Dominic R Demma; Roy D Dar
Journal:  Viruses       Date:  2021-06-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.